Applied DNA Q3 FY2025 revenue $304K, operating loss $3.7M; cash burn improves 19% sequentially

BNB PLUS CORP.

2025-Q3 EPS reported -$256.75 revenue$1,937,506

Total revenues $304K (down 36% YoY from $473K); operating loss $3.7M vs $3.3M loss in prior year.
Adjusted EBITDA negative $3.9M; monthly net cash burn $934K, down 19% sequentially and 25% YoY.
Received follow-on LineaDNA order >$600K from IVD manufacturer; added new U.S. mRNA CDMO customer.
Cash and equivalents $4.7M at June 30, 2025, including $723K from warrant exercises.
Company closed MDx Testing Services (discontinued ops) and executed 1:15 reverse stock split in June.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.